Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology & Hemotherapy Center F...
December 15 2020 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq: CERS) today announced that its
distribution partner, Companhia Energética Integrada (CEI), was
awarded a three-year contract with the HemoMinas Foundation
(“HemoMinas”) of Brazil for the INTERCEPT Blood System for
platelets. HemoMinas provides services and blood products in the
state of Minas Gerais, and the Hemocentro of Belo Horizonte – the
largest blood service of HemoMinas – distributes approximately
25,000 platelet doses to hospitals annually.
“We are honored to have been selected by HemoMinas to supply the
INTERCEPT Blood System for platelets in the southeastern state of
Minas Gerais,” said Hans Vermeij, Cerus’ senior director of
commercial operations in Latin America. “HemoMinas’ award is a
strong endorsement of the services and products offered by Cerus
and CEI, and the importance of pathogen reduced blood components in
Brazil,” Vermeij continued.
“The introduction of pathogen reduced blood components is an
important part of our blood safety strategy in Minas Gerais,” said
Dr. Maísa Aparecida Ribeiro, medical director at HemoMinas.
“INTERCEPT will provide a new foundational strategy for blood
safety to protect patients from endemic pathogens, such as Zika
virus, Dengue, and Chikungunya virus, and is a timely and
forward-looking step as we prepare for the inevitable next emerging
pathogen.”
“CEI is pleased to advance the adoption of the INTERCEPT Blood
System in Brazil as we partner with Cerus to establish a new level
of safety and availability for blood transfusions,” said Paulo
Pacheco, president of CEI. “HemoMinas is highly respected in Brazil
and delivers platelet products throughout the entire Minas Gerais
state, which has more than 20 million residents,” Pacheco said.
The INTERCEPT Blood System for platelets and plasma is the only
pathogen reduction system to receive approval from the Agência
Nacional de Vigilância Sanitária (ANVISA) for commercial use in
Brazil. Over 3.7 million whole blood and apheresis blood components
are collected annually in Brazil.
ABOUT HEMOMINAS
Established in 1989, the Minas Gerais Hematology and Hemotherapy
Center Foundation (HemoMinas) provides services, products, and
education in hematology, hemotherapy, cells, tissues. The
foundation also ensures unity and direction for state policies
related to hematology and hemotherapy, guaranteeing the safe and
sufficient supply of quality blood and blood products. HemoMinas
distributes approximately 25,000 platelet doses to hospitals
annually in the state of Minas Gerais. For more information about
Hemominas, visit www.hemominas.mg.gov.br.
ABOUT CEI GROUP
Founded in 1991 by the entrepreneur Paulo Cezar Pacheco, who has
more than 45 years of expertise in the health area, the CEI Group
portfolio of products boasts of prestigious world trademarks with
exclusive rights of distribution across Brazil. Its organizational
chart is made up of regional branches strategically placed, its own
sales team, and specialized technical assistance.
The organization is the market leader in the products that it
commercializes. The constant search for innovative products, an
integrated sales concept, and high quality of services, with the
focus on the needs and satisfaction of the customers, are the
strategies that have consolidated the company in the market.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Headquartered in Concord, California, the company
develops and supplies vital technologies and pathogen-protected
blood components to blood centers, hospitals, and ultimately
patients who rely on safe blood. The INTERCEPT Blood System for
platelets and plasma is available globally and remains the only
pathogen reduction system with both CE mark and FDA approval for
these two blood components. The INTERCEPT red blood cell system is
under regulatory review in Europe, and in late-stage clinical
development in the US. Also in the US, the INTERCEPT Blood System
for Cryoprecipitation is approved for production of Pathogen
Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product
for the treatment and control of bleeding associated with
fibrinogen deficiency, including massive hemorrhage. For more
information about Cerus, visit www.cerus.com and follow us on
LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201215005284/en/
Jessica Hanover – VP, Corporate Affairs Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024